A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.

导出原文传递

翻译打印收藏纠错

第一作者： Phillip Lr,Nicolson

第一单位： Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham , Birmingham, UK.

作者： Phillip Lr,Nicolson ^[1] ; John D,Welsh ^[2] ; Abhishek,Chauhan ^[3] ; Mark R,Thomas ^[1] ; Mark L,Kahn ^[2] ; Steve P,Watson ^[1]

作者单位： Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham , Birmingham, UK. ^[1] Department of Medicine and Cardiovascular Institute, University of Pennsylvania , Philadelphia, Pennsylvania, USA. ^[2] Centre for Liver Research, Institute of Immunology and Inflammation, and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, College of Medical and Dental Sciences, University of Birmingham , Birmingham, UK. ^[3] Centre of Membrane Proteins and Receptors, The Universities of Birmingham and Nottingham , The Midlands, UK. ^[4]

关键词 Btk COVID-19 platelets; thromboinflammation

主题词冠状病毒感染(Coronavirus Infections);人类(Humans);疾病大流行(Pandemics);肺炎, 病毒性(Pneumonia, Viral);蛋白激酶抑制剂(Protein Kinase Inhibitors)

DOI 10.1080/09537104.2020.1775189

PMID 32552307

发布时间 2022-03-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交